


17 December 2019

ASX Code: MXC

## Prescriptions number continues to grow above 1,800 including first prescriptions issued in Ireland

**MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company')**, a European based 'Seed to Medicine' bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce that it has reached over 1,800 prescriptions of its standardised, affordable cannabinoid medicines. This increase has been achieved from patients in Australia, the United Kingdom and with the recent additions of new patient special access approved markets of Brazil and Ireland following the recent approval for the sale of CannEpil® in these countries.

In addition, MGC Pharma has received its first purchase order from Brazil under its agreement with ONIX Empreendimentos e Participações ('Onix') which is currently being manufactured and is expected to be shipped by the end of December.



### Key Highlights:

- Prescriptions have increased over 25% from 1,400 at the end of November 2019 to pass 1,800 as at 16 December 2019, including from increasing numbers of returning patients
- First prescription received from Ireland following the very recent approval for the sale of CannEpil®
- Ireland is very strategic with respect to potential future approvals into other EU member states
- Average Prescription orders are currently at over 30 per business day
- Near term revenue continues to increase as prescription numbers grow in targeted markets

**Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented:** "First prescriptions in Ireland signify another milestone for MGC as we expand our product offering to new territories and thereby gain access to more potential customers. We continue on an upward trajectory, as we've increased our prescription numbers by more than 25% in just a few weeks. I'm confident that in 2020 we'll be able to deliver our phytocannabinoid derived medicines in even more jurisdictions as we continue to gain momentum."

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

## Further Information

MGC Pharma is pleased to have passed a further target as an emerging bio-pharma company during December, with prescriptions for its phytocannabinoid derived medicines reaching over 1,800 prescribed products across Australia, the UK, Brazil and now Ireland demonstrating its strengthening position in each market. The Company received first prescriptions from Ireland following the very recent approval for the sale of CannEpil® in the country, an important step in potential future approvals in other EU member states, and its first purchase order from Onix in Brazil. Recent passing of key legalisation of cannabis for medicinal uses in Brazil, is now expected to have a materially positive impact on prescription numbers from that country.

This growth includes patients returning for repeat orders and the Company is seeing current average prescription orders of over 30 per business day. In addition, a number of other patients are being treated with MGC Pharma products globally via participation in ongoing clinical research. The commercialisation of its portfolio of phytocannabinoid derived medicines is in line with its strategy of becoming a world-leading bio-pharma company through international distribution agreements.

CannEpil® and MXP100 are both proprietary MGC Pharma products that have been developed internally through the Company's Research and Development division and progressed through to commercialisation. This is in line with the Company's 'Seed to Medicine' strategy with the Company owning all the intellectual property through each stage of a product's development, from the genetics to finished pharmaceutical grade product.

The Company continues to work closely with its designated distributors to onboard further clinics, in addition to independent medical professionals, in each region increasing patient access to its phytocannabinoid derived medicines under the relevant legislation in each jurisdiction.

--Ends--

### Authorised for release by the Board, for further information please contact:

#### UK IR/Media Advisors

Catherine Leftley/Megan Dennison  
St Brides Partners Ltd  
+44 (0) 207 236 1177  
[megan@stbridespartners.co.uk](mailto:megan@stbridespartners.co.uk)  
[catherine@stbridespartners.co.uk](mailto:catherine@stbridespartners.co.uk)

#### MGC Pharmaceuticals Ltd

Brett Mitchell  
Executive Chairman  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

## About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC, OTCQB: MGCLF) is a European based bio-pharma company supplying phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting three widespread medical conditions - epilepsy, dementia and IBS – and has further products in the development pipeline.

Employing its 'Seed to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and recent research conducted in collaboration with the National Institute of Biology and University Medical Centre Ljubljana, highlighted the positive impact of using specific phytocannabinoid formulations in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia and the UK and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. In order to meet the demands of becoming a key global supplier the company is constructing a 15,720m<sup>2</sup> GMP state of the art facility in Malta.

Follow us through our social media channels    